Dendreon's Gold tops 'Worst Biotech CEO' poll

Mitch Gold and his struggling biotech Dendreon ($DNDN) can't catch a break since disappointing Wall Street with lackluster sales of the prostate cancer drug Provenge. TheStreet announced Gold was voted this year's worst chief executive in a poll that drew 1,800 votes. It's more proof of how a disappointing drug launch can quickly change the fortunes of a biotech CEO; Gold was voted as TheStreet's best chief last year after his company gained the first-ever FDA nod for a cancer vaccine. Article

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.